Postoperative Changes in Skeletal Muscle Mass Predict Survival of Patients With Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy

Clinical Genitourinary Cancer

Volumn 15, Issue 2, 2017, Pages e229-e238

  Fukushima, Hiroshi ^a   Nakanishi, Yasukazu ^a   Kataoka, Madoka ^a   Tobisu, Ken ichi ^a   Koga, Fumitaka ^a  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

Author keywords

CN; Kinetics; mRCC; Overall survival; Skeletal muscle index

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; HEMOGLOBIN; LACTATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; BODY MASS; BONE METASTASIS; BONE SCINTISCANNING; BRAIN METASTASIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; IMAGE ANALYSIS; JAPANESE (PEOPLE); KIDNEY METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; METASTASIS RESECTION; MUSCLE MASS; NEPHRECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITIONAL STATUS; OPERATION DURATION; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; RETROSPECTIVE STUDY; SARCOPENIA; SKELETAL MUSCLE; SURGICAL PATIENT; TREATMENT OUTCOME; CARCINOMA, RENAL CELL; DIAGNOSTIC IMAGING; KIDNEY NEOPLASMS; MIDDLE AGED; PROCEDURES; PROGNOSIS; SURVIVAL ANALYSIS; VERY ELDERLY; X-RAY COMPUTED TOMOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; CYTOREDUCTION SURGICAL PROCEDURES; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; NEPHRECTOMY; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84994506121     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2016.08.004     Document Type: Article

References (37)

1. 1 McLaughlin, J.K., Lipworth, L., Epidemiologic aspects of renal cell cancer. Semin Oncol 27 (2000), 115–123.
2. 2 Motzer, R.J., Bander, N.H., Nanus, D.M., Renal-cell carcinoma. N Engl J Med 335 (1996), 865–875.
3. 3 Motzer, R.J., Hutson, T.E., Cella, D., et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369 (2013), 722–731.
4. 4 Motzer, R.J., Hutson, T.E., Olsen, M.R., et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol 30 (2012), 1371–1377.
5. 5 Flanigan, R.C., Mickisch, G., Sylvester, R., Tangen, C., Van Poppel, H., Crawford, E.D., Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171 (2004), 1071–1076.
6. 6 Choueiri, T.K., Xie, W., Kollmannsberger, C., et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol 185 (2011), 60–66.
7. 7 Heng, D.Y., Wells, J.C., Rini, B.I., et al. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol 66 (2014), 704–710.
8. 8 Fearon, K., Strasser, F., Anker, S.D., et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12 (2011), 489–495.
9. 9 Martin, L., Birdsell, L., Macdonald, N., et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 31 (2013), 1539–1547.
10. 10 Prado, C.M., Lieffers, J.R., McCargar, L.J., et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 9 (2008), 629–635.
11. 11 Harimoto, N., Shirabe, K., Yamashita, Y.I., et al. Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma. Br J Surg 100 (2013), 1523–1530.
12. 12 Sabel, M.S., Lee, J., Cai, S., Englesbe, M.J., Holcombe, S., Wang, S., Sarcopenia as a prognostic factor among patients with stage III melanoma. Ann Surg Oncol 18 (2011), 3579–3585.
13. 13 Fukushima, H., Yokoyama, M., Nakanishi, Y., Tobisu, K., Koga, F., Sarcopenia as a prognostic biomarker of advanced urothelial carcinoma. PLoS One, 10, 2015, e0115895.
14. 14 Psutka, S.P., Boorjian, S.A., Moynagh, M.R., et al. Decreased skeletal muscle mass is associated with an increased risk of mortality after radical nephrectomy for localized renal cell cancer. J Urol 195 (2016), 270–276.
15. 15 Fukushima, H., Nakanishi, Y., Kataoka, M., Tobisu, K., Koga, F., Prognostic significance of sarcopenia in patients with metastatic renal cell carcinoma. J Urol 195 (2016), 26–32.
16. 16 Motzer, R.J., Bacik, J., Schwartz, L.H., et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22 (2004), 454–463.
17. 17 Heng, D.Y., Xie, W., Regan, M.M., et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27 (2009), 5794–5799.
18. 18 WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 363 (2004), 157–163.
19. 19 Clavien, P.A., Barkun, J., de Oliveira, M.L., et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 250 (2009), 187–196.
20. 20 Saito, K., Tatokoro, M., Fujii, Y., et al. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma. Eur Urol 55 (2009), 1145–1153.
21. 21 Tatokoro, M., Saito, K., Iimura, Y., Fujii, Y., Kawakami, S., Kihara, K., Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy. J Urol 180 (2008), 515–519.
22. 22 Greene, F.L., Page, D.L., Fleming, I.D., Part IX—Genitourinary Sites. AJCC Cancer Staging Manual, 6th ed., 2002, Springer-Verlag, New York.
23. 23 Mostofi, F., Davis, C., Histological Classification of Kidney Tumors. 1998, Springer, Berlin.
24. 24 Shen, W., Punyanitya, M., Wang, Z., et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol (1985) 97 (2004), 2333–2338.
25. 25 Sharma, P., Zargar-Shoshtari, K., Caracciolo, J.T., et al. Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Urol Oncol 33 (2015), 339.e317–339.e323.
26. 26 Choi, Y., Oh, D.Y., Kim, T.Y., et al. Skeletal muscle depletion predicts the prognosis of patients with advanced pancreatic cancer undergoing palliative chemotherapy, independent of body mass index. PLoS One, 10, 2015, e0139749.
27. 27 Hamaguchi Y, Kaido T, Okumura S, et al. Proposal for new diagnostic criteria for low skeletal muscle mass based on computed tomography imaging in Asian adults [e-pub ahead of print]. Nutrition http://dx.doi.org/10.1016/j.nut.2016.04.003.
28. 28 Miyamoto, Y., Baba, Y., Sakamoto, Y., et al. Sarcopenia is a negative prognostic factor after curative resection of colorectal cancer. Ann Surg Oncol 22 (2015), 2663–2668.
29. 29 Peng, P., Hyder, O., Firoozmand, A., et al. Impact of sarcopenia on outcomes following resection of pancreatic adenocarcinoma. J Gastrointest Surg 16 (2012), 1478–1486.
30. 30 Stene, G.B., Helbostad, J.L., Amundsen, T., et al. Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer. Acta Oncol 54 (2015), 340–348.
31. 31 Hanai, T., Shiraki, M., Ohnishi, S., et al. Rapid skeletal muscle wasting predicts worse survival in patients with liver cirrhosis. Hepatol Res 46 (2016), 743–751.
32. 32 Fearon, K.C., Glass, D.J., Guttridge, D.C., Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab 16 (2012), 153–166.
33. 33 Sakai, I., Miyake, H., Hinata, N., Fujisawa, M., Improved survival in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy in the era of targeted therapy. Int J Clin Oncol 19 (2014), 674–678.
34. 34 Pappalardo, G., Almeida, A., Ravasco, P., Eicosapentaenoic acid in cancer improves body composition and modulates metabolism. Nutrition 31 (2015), 549–555.
35. 35 Huillard, O., Mir, O., Peyromaure, M., et al. Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. Br J Cancer 108 (2013), 1034–1041.
36. 36 Naito, S., Yamamoto, N., Takayama, T., et al. Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur Urol 57 (2010), 317–325.
37. 37 Tatokoro, M., Fujii, Y., Kawakami, S., et al. Phase-II trial of combination treatment of interferon-alpha, cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin-system inhibitor (I-CCA therapy) for advanced renal cell carcinoma. Cancer Sci 102 (2011), 137–143.